Cellectis SA - Asset Resilience Ratio
Cellectis SA (CLLS) has an Asset Resilience Ratio of 49.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cellectis SA (CLLS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Cellectis SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cellectis SA assets under control.
Liquid Assets Composition Over Time
This chart breaks down Cellectis SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Cellectis SA strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $131.26 Million | 49.09% |
| Total Liquid Assets | $131.26 Million | 49.09% |
Asset Resilience Insights
- Very High Liquidity: Cellectis SA maintains exceptional liquid asset reserves at 49.09% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cellectis SA Industry Peers by Asset Resilience Ratio
Compare Cellectis SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Cellectis SA (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Cellectis SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 44.68% | $145.08 Million | $324.72 Million | +14.16pp |
| 2024-12-31 | 30.52% | $117.06 Million | $383.54 Million | +10.44pp |
| 2023-12-31 | 20.08% | $67.11 Million | $334.27 Million | +17.05pp |
| 2022-12-31 | 3.03% | $7.91 Million | $261.22 Million | +2.90pp |
| 2021-12-31 | 0.13% | $499.00K | $382.08 Million | -5.64pp |
| 2020-12-31 | 5.77% | $27.09 Million | $469.47 Million | +1.41pp |
| 2019-12-31 | 4.36% | $20.39 Million | $467.47 Million | +4.28pp |
| 2018-12-31 | 0.08% | $388.00K | $500.84 Million | -12.12pp |
| 2017-12-31 | 12.20% | $40.60 Million | $332.88 Million | +1.16pp |
| 2016-12-31 | 11.04% | $36.51 Million | $330.68 Million | +10.57pp |
| 2014-12-31 | 0.47% | $787.00K | $167.34 Million | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more